Hallucinogen-Related Hospitalizations Linked to Higher Mortality
-
By
March 10, 2025
-
2 min
A population-based cohort study in Ontario, published in the Canadian Medical Association Journal, revealed that patients requiring acute hospital care for hallucinogen use had an elevated risk of mortality, particularly from suicide, unintentional drug poisoning, respiratory disease, and cancer. Lead study author Daniel T. Myran and colleagues highlighted the importance of these findings in clinical and policy decision-making, especially considering the increasing use of hallucinogens and associated problematic use. The study emphasized the need for further research into associated risks, particularly in nonmedical settings.
1. Patients requiring hospital care for hallucinogen use had a heightened risk of mortality, particularly from suicide, unintentional drug poisoning, respiratory disease, and cancer. 2. The mortality risk remained elevated even after excluding patients with comorbid mental health or substance use disorders. 3. Most common hallucinogens linked to hospitalizations included lysergic acid diethylamide, psilocybin, phencyclidine, ketamine, and 3,4-methylenedioxymethamphetamine. 4. Primary reasons for admission were harmful use, poisoning, intoxication, and withdrawal. 5. Patients hospitalized for hallucinogen use had a higher mortality risk compared with alcohol-related acute care visits but a lower risk compared with opioid-related hospitalizations. 6. The study emphasized the need for further research into associated risks, particularly in nonmedical settings.
Listen Tab content
